Osteoporosis and Cardiovascular Risk
Osteoporosis and cardiovascular diseases are two of the major public health problems: both are associated with high morbidity and mortality, increased recourse to hospital services, loss of independence, increased risk of institutionalization and high health-related costs. The socio-economic consequences of both these diseases are very important bearing in mind the facts that OP is the second highest world health problem after CVD, and this number will increase with the growth of the elderly population over the next decades.
- 11.Frost ML, Grella R, Millasseau SC, Jiang BY, Hampson G, Fogelman I, Chowienczyk PJ. Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcif Tissue Int. 2008;83(2):112–20.CrossRefPubMedGoogle Scholar
- 16.D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Investig. 2009;32(4 Suppl):6–9.Google Scholar
- 18.Evrard S, Delanaye P, Kamel S. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta. 2014;438C:401–14.Google Scholar
- 32.Samelson EJ, Miller PD, Christiansen C. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29:450–7.CrossRefPubMedPubMedCentralGoogle Scholar